IA
BMRN icon

IPL Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

IPL Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-129,500
Closed -$11.4M – 17
2017
Q1 		$11.4M Hold
129,500
– – 4.89% 11
2016
Q4 		$10.7M Buy
+129,500
New +$11.1M 2.98% 14

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IPL Advisers's BMRN Position: Q2 2017 in Review

IPL Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 129,500 shares — an estimated $11.4M sold.

IPL Advisers first reported a position in BMRN in Q4 2016 and held it in 2 quarters. The position peaked at $11.4M in Q1 2017. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • IPL Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • IPL Advisers sold 129,500 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $11.4M.
  • IPL Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • IPL Advisers's BioMarin Pharmaceuticals position peaked at $11.4M in Q1 2017.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on IPL Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.